stooonks

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

× 🔎 Explain it

---

Takeda Pharmaceutical Company Limited

Takeda makes and sells medicines that treat rare diseases, cancer, and gut and brain conditions.

Takeda is one of the world's biggest drug companies, and it runs two main kinds of business. First, it sells prescription medicines — pills and injectable drugs that treat rare diseases, cancer, and conditions of the gut and the brain. Second, it has a smaller plasma business, where it turns donated blood plasma into therapies for people with immune and bleeding disorders. Its customers aren't regular shoppers; they're hospitals, clinics, and pharmacies, and the bills are usually paid by insurers or government health programs. The rare-disease and plasma drugs bring in the steadiest money because they're hard to copy and patients often stay on them for years. Think of it as a company that bets big and early on medicines most other firms ignore, then earns steady profits once those drugs reach patients.

How does it actually make money? When a drug wins approval from regulators, Takeda sells it at high prices to a small number of patients — sometimes only a few thousand worldwide — which means even modest drugs can pull in hundreds of millions of dollars. Its biggest sellers are treatments for inflammatory bowel disease, a rare swelling disorder called hereditary angioedema, and a narcolepsy drug, alongside a large plasma-therapy portfolio. Cancer and neuroscience medicines round things out. Growth lately has leaned on those rare-disease and plasma franchises while older drugs lose patent protection and face cheap generic copies, a constant headwind. Annual revenue runs around the equivalent of thirty billion dollars, and the company spends roughly a fifth of that on research to refill the pipeline.

Takeda started in 1781 as a small medicine merchant in Osaka, and its modern shape came from a huge 2019 purchase of the Irish drugmaker Shire, which pushed it into rare diseases and plasma and loaded it with debt. Paying that debt down has been a big use of its cash, along with dividends to shareholders and deals to buy or partner on new drugs rather than build everything itself. The key things to watch are whether its newest medicines keep growing, how fast it shrinks the debt pile, and whether its research labs deliver the next big seller before older drugs fade.

Saved answer · last researched 12 Oct 2026